[June 10, 2011]

PanGenex Shareholder Update

PanGenex Corporation ("PanGenex" or "the Company") (Pink Sheets: PGCX), a nutraceutical and dietary supplement developer; today provided the following update to shareholders and other interested parties.

First, the Company has invested millions of dollars in developing what it believes are "Best of Breed" products that target soft tissue calcification. The products are more fully described at its website, www.HeartHealthyWorld.com.

Second, the Company historically sold through physicians, or directly to customers. However, we are now ready to launch a more comprehensive marketing plan that will include a viral internet strategy, as well as engaging firms that have proven reach to retail outlets.

About PanGenex Corporation

PanGenex Corporation pursues business opportunities in the $70 billion nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, PanGenex develops and markets sector-leading, patented or patent-pending, condition-specific nutraceticals and topical over-the-counter (OTC) drugs and personal care products. PanGenex principal products Calci-Clear, LIPIDEME and Omeganol, address Soft Tissue Calcification (STC), an abnormal hardening or thickening of soft tissues (such as arteries) which is linked to over 50% of chronic diseases and presently affects an estimated 196 million or 60 percent of all Americans. Many of its products contain the purest grade of nutraceutical components available anywhere without a prescription. Since 2006, PanGenex has voluntarily submitted its product labels to the FDA without incidence. PanGenex products are sold to healthcare practitioners in 20 U.S. states, Canada, Puerto Rico, Canada, Brazil and Australia, in fine retail establishments and on the Internet at www.HeartHealthyWorld.com.

This press release contains "forward-looking statements," which are statements related to future, not past, events. In this context, the forward-looking statements often include statements regarding our goals, plans, projections and guidance regarding our financial position, results of operations, market position, pending and potential future acquisitions and business strategy, and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks" or "will." Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) our cost of financing, (e) our ability to complete acquisitions and dispositions and the risks associated therewith, and (f) our ability to retain key personnel. These factors, as well as additional factors, could affect our forward-looking statements. We urge you to carefully consider this information. We undertake no duty to update our forward-looking statements, including our earnings outlook. The statements in this press release have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

[ Back To TMCnet.com's Homepage ]